These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22002767)

  • 21. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
    Prater SN; Patel TT; Buckley AF; Mandel H; Vlodavski E; Banugaria SG; Feeney EJ; Raben N; Kishnani PS
    Orphanet J Rare Dis; 2013 Jun; 8():90. PubMed ID: 23787031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of exercise training during infusion on late-onset Pompe disease patients receiving enzyme replacement therapy.
    Terzis G; Krase A; Papadimas G; Papadopoulos C; Kavouras SA; Manta P
    Mol Genet Metab; 2012 Dec; 107(4):669-73. PubMed ID: 23146291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
    Katzin LW; Amato AA
    J Clin Neuromuscul Dis; 2008 Jun; 9(4):421-31. PubMed ID: 18525427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
    Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
    Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pompe disease treated with enzyme replacement therapy in pregnancy].
    Grosz Z; Várdi KV; Molnár JM
    Ideggyogy Sz; 2020 Sep; 73(9-10):339-344. PubMed ID: 33035415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early administration of enzyme replacement therapy for Pompe disease: short-term follow-up results.
    Hamdan MA; Almalik MH; Mirghani HM
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S431-6. PubMed ID: 19067231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
    Koeberl DD; Luo X; Sun B; McVie-Wylie A; Dai J; Li S; Banugaria SG; Chen YT; Bali DS
    Mol Genet Metab; 2011 Jun; 103(2):107-12. PubMed ID: 21397538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Research advances in the diagnosis and treatment of Pompe disease].
    Zhang XT; Ren WD
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):588-593. PubMed ID: 30022764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic approaches in glycogen storage disease type II/Pompe Disease.
    Schoser B; Hill V; Raben N
    Neurotherapeutics; 2008 Oct; 5(4):569-78. PubMed ID: 19019308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH; Hwu WL; Lee NC
    Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease.
    van Gelder CM; Hoogeveen-Westerveld M; Kroos MA; Plug I; van der Ploeg AT; Reuser AJ
    J Inherit Metab Dis; 2015 Mar; 38(2):305-14. PubMed ID: 24715333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-α-glucosidase in Pompe's iPSCs.
    Higuchi T; Kawagoe S; Otsu M; Shimada Y; Kobayashi H; Hirayama R; Eto K; Ida H; Ohashi T; Nakauchi H; Eto Y
    Mol Genet Metab; 2014 May; 112(1):44-8. PubMed ID: 24642446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease.
    Douillard-Guilloux G; Richard E; Batista L; Caillaud C
    J Gene Med; 2009 Apr; 11(4):279-87. PubMed ID: 19263466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
    Del Rizzo M; Fanin M; Cerutti A; Cazzorla C; Milanesi O; Nascimbeni AC; Angelini C; Giordano L; Bordugo A; Burlina AB
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S389-93. PubMed ID: 20830524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy.
    van der Meijden JC; Kruijshaar ME; Harlaar L; Rizopoulos D; van der Beek NAME; van der Ploeg AT
    J Inherit Metab Dis; 2018 Nov; 41(6):1205-1214. PubMed ID: 29556838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzyme replacement therapy in severe adult-onset glycogen storage disease type II.
    Ravaglia S; Danesino C; Pichiecchio A; Repetto A; Poloni GU; Rossi M; Fratino P; Moglia A; Costa A
    Adv Ther; 2008 Aug; 25(8):820-9. PubMed ID: 18704279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency.
    Vianello A; Semplicini C; Paladini L; Concas A; Ravaglia S; Servidei S; Toscano A; Mongini T; Angelini C; Pegoraro E
    Lung; 2013 Oct; 191(5):537-44. PubMed ID: 23839583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.